Ionis Pharmaceuticals Inc. ( (IONS) ) has released its Q3 earnings. Here is a breakdown of the information Ionis Pharmaceuticals Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapies for serious diseases, with a strong presence in neurology and cardiometabolic disease sectors.
In its third quarter of 2025, Ionis Pharmaceuticals reported significant progress in its product pipeline and financial performance, including a 17% increase in revenue compared to the previous year. The company highlighted the successful launch of new products and advancements in clinical trials.
Key financial metrics for the third quarter include a total revenue of $157 million, driven by the launch of TRYNGOLZA and increased royalty revenues. Despite a net loss of $129 million, the company’s revenue growth and strategic partnerships, such as the $280 million deal with Ono Pharmaceutical, underscore its robust market position. Ionis also reported positive clinical results for olezarsen and zilganersen, setting the stage for future product launches.
Looking ahead, Ionis anticipates further growth with upcoming product launches and regulatory submissions. The company expects to achieve cash flow breakeven by 2028, driven by its expanding product portfolio and strategic collaborations. Ionis remains committed to advancing its innovative RNA-targeted therapies to meet high patient needs.